|Mr. Stephen S. Yoder||CEO, Pres & Director||754.64k||N/A||1976|
|Dr. Allan Reine||Sr. VP, CFO & Treasurer||562.12k||N/A||1975|
|Dr. Louis A. Matis||Sr. VP & Chief Devel. Officer||549.9k||N/A||1951|
|Mr. Claus Schalper MBA||Co-Founder & Sr. Advisor||N/A||N/A||N/A|
|Maria Kelman||Director of Investor Relations||N/A||N/A||N/A|
Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids. Its lead respiratory program includes PRS-060, a drug candidate, which is in Phase I clinical trial that binds to IL-4Ra for the treatment of asthma and other inflammatory diseases; and lead immuno-oncology program comprises PRS-343, a bispecific protein that is in Phase I clinical trial for oncology diseases. The company is also developing PRS-344, a bispecific anticalin-antibody fusion protein that is in preclinical stage for oncology diseases; and PRS-080, a polyethylene glycol conjugated anticalin protein that is in Phase IIa clinical trial to target hepcidin for the treatment of functional iron deficiency in anemic patients with chronic kidney disease or in end-stage renal disease patients requiring dialysis, as well as other drugs. It has strategic partnerships with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seattle Genetics Inc., as well as others; and non-strategic license or option agreements with Aska Pharmaceutical Co., Ltd., F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc., and Sanofi, as well as license agreements with TUM, Enumeral Biomedical Holdings, Inc., and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. Pieris Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.
Pieris Pharmaceuticals, Inc.’s ISS Governance QualityScore as of July 29, 2019 is 10. The pillar scores are Audit: 10; Board: 9; Shareholder Rights: 8; Compensation: 5.